Zadik Hazan
Hoofd Techniek/Wetenschap/O&O bij Hy BioPharma, Inc.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Yitzhak Peterburg | M | 73 |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
Michael Steinberg | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
Sharon Falach-Kovalsky | F | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
Marius Nacht | M | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
Shlomo Shalev | M | 62 |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
Alfonso Tobia | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
Bernard Cabana | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Israël | 4 | 57.14% |
Verenigde Staten | 3 | 42.86% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Zadik Hazan
- Persoonlijk netwerk